Supraphysiological Glucocorticoid Doses and Pitfalls of Annual Biomarker Monitoring in Adults With CAH
Clinical Endocrinology · 2026-09 · 105 (3) · 360-362
DOI: 10.1111/cen.70172 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Endocrinology, online erschienen am 18.06.2026. Verfasst von Jakob Bolinder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Management of congenital adrenal hyperplasia (CAH) remains a balancing act between androgen excess and glucocorticoid over-exposure. We performed a retrospective review of 58 adults with 21‐hydroxylase deficiency (21‐OHD) followed at the Department of Endocrinology at the Sahlgrenska University Hospital during the period 2020–2024. While the limited study size and retrospective design warrant cautious interpretation, the findings nonetheless point to important challenges in current practice
Autor:innen und Institutionen
- Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
ORCID-Profile: Jakob Bolinder
Zitieren
APA
Bolinder, J., Ragnarsson, O., & Johansson, G. (2026). Supraphysiological Glucocorticoid Doses and Pitfalls of Annual Biomarker Monitoring in Adults With CAH. Clinical Endocrinology, 105(3), 360-362. https://doi.org/10.1111/cen.70172
Vancouver
Bolinder J, Ragnarsson O, Johansson G. Supraphysiological Glucocorticoid Doses and Pitfalls of Annual Biomarker Monitoring in Adults With CAH. Clinical Endocrinology. 2026;105(3):360-362. doi:10.1111/cen.70172
BibTeX
@article{Bolinder2026,
author = {Bolinder, Jakob and Ragnarsson, Oskar and Johansson, Gudmundur},
title = {Supraphysiological Glucocorticoid Doses and Pitfalls of Annual Biomarker Monitoring in Adults With CAH},
journal = {Clinical Endocrinology},
year = {2026},
volume = {105},
number = {3},
pages = {360--362},
doi = {10.1111/cen.70172}
}
EUVIMED